| Effect | Decrease |
| Values | (10⁹/L change). Within group. Placebo: 0.04 ± 0.1. Curcumin: −0.3 ± 0.1 |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 81 |
| Sex | Both Genders |
| Age Range | 30-44, 45-64, 65+ |
| Body Types | Obese, Overweight |
In a randomized, double-blind, placebo-controlled trial, 81 participants with insulin resistance who were at a high risk for type 2 diabetes were allocated into roughly equal groups to take 1,000 mg of phytosomal curcumin, 1.2 g of DHA + EPA, the combination, or placebo for 12 weeks.
The primary outcomes were measures related to glucose control, primarily HbA1c, and including fasting glucose, fasting insulin, and insulin sensitivity. The curcumin group didn't see a statistically significant change in Hba1C or fasting glucose compared with placebo. Serum insulin and insulin resistance were reduced significantly in the curcumin group compared with placebo.
Triglycerides, atherogenic index and InsuTAG were significantly reduced compared with placebo in the curcumin group, but HDL was unaffected. Statistical comparisons between specific groups were not made available for the other measures, but white blood cells, lymphocytes, and monocytes were significantly reduced compared with the baseline in the curcumin group.
